JAK2 and myeloproliferative neoplasm: A recent study investigated the frequency and function of CD4+ T cell subsets in 50 MPN patients at baseline as well as during treatment with either ruxolitinib or fedratinib (SAR302503; TG101348), a selective JAK2 inhibitor (64).